| Light, short-term | Light, long-term | Heavy, short-term | Heavy, long-term | P value |
---|---|---|---|---|---|
 | 32(16.8%) | 18(8.4%) | 57(29.8%) | 86(45.0%) |  |
Age, yr, median | 40(20-58) | 50(36-60) | 39(24-59) | 49(10-66) | 0.452 |
Gender | Â | Â | Â | Â | 0.005 |
Female | 1(3.1) | 1(12.5) | 0 | 0 | Â |
Male | 31(96.9) | 17(87.5) | 57(100) | 86(100) | Â |
T stage | Â | Â | Â | Â | 0.368 |
1-2 | 7(21.9) | 1(5.6) | 8(14.0) | 13(15.1) | Â |
3-4 | 25(78.1) | 17(94.4) | 49(86.0) | 73(84.9) | Â |
N stage | Â | Â | Â | Â | 0.463 |
0-1 | 16(48.5) | 6(33.3) | 25(43.9) | 45(52.3) | Â |
2-3 | 17(51.5) | 12(66.7) | 32(56.1) | 41(47.7) | Â |
Clinical stage | Â | Â | Â | Â | 0.189 |
3 | 15(46.9) | 14(75.0) | 34(59.6) | 43(50.0) | Â |
4 | 17(53.1) | 4(25.0) | 23(40.4) | 43(50.0) | Â |
Treatment arm | Â | Â | Â | Â | 0.641 |
IC + CCRT | 16(50.0) | 11(61.1) | 32(56.1) | 41(47.7) |  |
IC + RT | 16(50.0) | 7(38.9) | 25(43.9) | 45(52.3) |  |
RT dose(Gy),median(range) | 72(68-78) | 72(68-78) | 72(68-78) | 72(68-78) | 0.118 |
CT course, median(range) | 2(2-5) | 32(1-5) | 22(1-5) | 22(1-5) | 0.470 |
RT interruption | Â | Â | Â | Â | Â |
Yes | 2(6.2) | 0(0) | 1(1.8) | 1(1.2) | 0.337 |
No | 30(93.8) | 18(100) | 55(98.2) | 85(98.8) | Â |
AMT | Â | Â | Â | Â | 0.731 |
1-2 | 30(93.8) | 18(100) | 52(92.9) | 80(93.0) | Â |
3-4 | 2(6.2) | 0(0) | 4(7.1) | 6(7.0) | Â |
VCA-IgA | Â | Â | Â | Â | 0.330 |
Positive(≥1:80) | 30(93.8) | 17(94.4) | 47(83.9) | 79(91.9) |  |
Negative | 2(6.3) | 1(5.6) | 9(16.1) | 7(8.1) | Â |
EA-IgA | Â | Â | Â | Â | 0.121 |
Positive(≥1:10) | 27(84.4) | 17(94.4) | 39(69.6) | 67(77.9) |  |
Negative | 5(15.6) | 1(5.6) | 17(30.4) | 19(22.1) | Â |
Median follow-up yr (range) | 6.8(0.5-8.7) | 6.9(1.1-8.3) | 6.5(0.2-8.6) | 6.2(0.6-9.0) | 0.572 |